<DOC>
	<DOCNO>NCT02257567</DOCNO>
	<brief_summary>This study multicenter , open-label study polatuzumab vedotin administer intravenous ( IV ) infusion combination standard dose bendamustine ( B ) rituximab ( R ) obinutuzumab ( G ) participant relapse refractory follicular lymphoma ( FL ) diffuse large B-cell lymphoma ( DLBCL ) . The study comprise two stage : Phase Ib safety run-in stage Phase II stage . The anticipated time treatment 18 week participant DLBCL 24 week participant FL .</brief_summary>
	<brief_title>A Study Polatuzumab Vedotin ( DCDS4501A ) Combination With Rituximab Obinutuzumab Plus Bendamustine Participants With Relapsed Refractory Follicular Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Histologically confirm relapsed refractory FL ( Grades 1 , 2 , 3a ) relapse refractory DLBCL If participant receive prior bendamustine , response duration must great ( &gt; ) 1 year ( participant relapse disease prior regimen ) At least one bidimensionally measurable lesion image scan define &gt; 1.5 centimeter ( cm ) long dimension Confirmed availability archival freshly collect tumor tissue Life expectancy least 24 week Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Adequate hematological function unless inadequate function due underlying disease History severe allergic anaphylactic reaction humanize murine monoclonal antibody ( MAbs , recombinant antibodyrelated fusion protein ) know sensitivity allergy murine product Contraindication bendamustine , rituximab , obinutuzumab Prior use MAb , radioimmunoconjugate , antibodydrug conjugate ( ADC ) within 4 week 5 halflives Cycle 1 Day 1 Treatment radiotherapy , chemotherapy , immunotherapy , immunosuppressive therapy , investigational agent purpose treat cancer within 2 week prior Cycle 1 Day 1 Ongoing corticosteroid use &gt; 30 mg per day prednisone equivalent , purpose lymphoma symptom control Completion autologous stem cell transplant ( SCT ) within 100 day prior Cycle 1 Day 1 Prior allogeneic SCT Eligibility autologous SCT Grade 3b FL History transformation indolent disease DLBCL Primary secondary CNS lymphoma Current Grade &gt; 1 peripheral neuropathy Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include significant cardiovascular disease ( New York Heart Association Class III IV cardiac disease , myocardial infarction within last 6 month , unstable arrhythmia , unstable angina ) significant pulmonary disease ( include obstructive pulmonary disease history bronchospasm ) Known active bacterial , viral , fungal , mycobacterial , parasitic , infection ( exclude fungal infection nail bed ) study enrollment major episode infection require treatment IV antibiotic hospitalization within 4 week prior Cycle 1 Day 1 Suspected latent tuberculosis Positive test result chronic hepatitis B virus ( HBV ) infection hepatitis C virus ( HCV ) antibody Known history human immunodeficiency virus ( HIV ) seropositive status know infection human Tcell leukemia virus 1 ( HTLV1 ) virus Women pregnant lactate intend become pregnant within year last dose study treatment rituximab cohort within 18 month last dose obinutuzumab cohort Evidence laboratory abnormality standard renal , hepatic , coagulation function test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>